Combination treatments for hypertension most often include a reninangiotensin-aldosterone system (RAAS) inhibitor. However, systolic blood pressure (SBP) remains difficult to control. Non-RAAS-inhibiting strategies such as calcium channel blocker/thiazide-like diuretic combinations may offer effective alternatives.
Original article
Recent data have shown that over 70% of hypertensive patients taking combination treatments are being prescribed a renin-angiotensin-aldosterone system (RAAS) inhibitor as 1 of the 2 components. 1 A large percentage of treated hypertensive patients, mainly in the elderly population, however, are still not reaching blood pressure (BP) control goals due to difficulties in lowering systolic BP (SBP). [1] [2] [3] [4] RAAS inhibitors are often used in combination treatments to counter the plasma renin activation induced by natriuretic drugs such as diuretics or calcium channel blockers (CCB). For diabetic patients, the impetus to include a RAAS inhibitor is even stronger as European guidelines support prescribing nephroprotective treatments. 5 However, in the context of insufficient BP reduction, it may be time to re-evaluate the assumption that RAAS inhibition is always needed to reach long-term BP control. For instance, in patients with low baseline renin levels, additional decreases in renin due to RAAS inhibition may not be beneficial. By some estimates, such patients constitute 30% of patients with essential hypertension. 6 Strategies that combine 2 non-RAAS-inhibiting therapies such as CCB/thiazide diuretic combinations are based on solid clinical evidence and have been listed by European guidelines among the preferred choices for many years. 5, 7 The VALUE trial, for instance, reported significantly reduced myocardial infarction with amlodipine/hydrochlorothiazide treatment compared to valsartan/hydrochlorothiazide treatment. 8 Moreover, the FEVER study showed a significant reduction of stroke with the hydrochlorothiazide/CCB combination compared to the hydrochlorothiazide/placebo control group (receiving antihypertensive agents other than CCBs). 9 Among possible CCB/thiazide diuretic combinations, significant evidence suggests that the combination of amlodipine, a third generation CCB, with indapamide slow release (SR), a thiazide-like diuretic, would be safe and effective. Both indapamide and amlodipine have been shown to reduce SBP effectively and to improve long-term cardiovascular outcomes. 8, [10] [11] [12] [13] [14] [15] [16] In a meta-analysis of 80 randomized controlled trials, treatment with indapamide SR had the greatest average effect on SBP (−22 mm Hg) and amlodipine performed better than 11 of the 15 other drugs (−16 mm Hg). 11 In addition, in the NATIVE study in which a subgroup of patients with mild-to-moderate hypertension were treated with amlodipine with add-on indapamide SR, a mean decrease in SBP of 33 mm Hg was noted after 3 months of therapy and 84% of patients reached their SBP targets. 17 Lastly, unlike thiazide diuretic hydrochlorothiazide, indapamide has been shown to be metabolically neutral in a wide range of patients and to have little effect on glucose levels, lipid levels, and renal function. [17] [18] [19] In fact, in patients with impaired renal function, indapamide has been shown to increase creatinine clearance. 20, 21 Thus, the efficacy and safety profiles of indapamide SR and amlodipine are such that their combination may offer an alternative choice for the treatment of essential hypertension. The objective of the study was to evaluate, through a retrospective analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial, the long-term antihypertensive efficacy and safety of combination indapamide SR/amlodipine in comparison with that of enalapril/amlodipine in hypertensive patients with type 2 diabetes mellitus and microalbuminuria.
METHODS
Data from the NESTOR trial were analyzed in this retrospective, post-hoc analysis. As previously described, the NESTOR trial was a randomized, controlled, double-blind study conducted in 570 patients with mild-to-moderate essential hypertension, controlled type 2 diabetes mellitus, and persistent microalbuminuria. 22 Mild-to-moderate hypertension was defined as a supine SBP ≥140 and <180 mm Hg with a supine diastolic BP (DBP) <110 mm Hg or as isolated systolic hypertension defined as supine SBP ≥160 and <180 mm Hg and a supine DBP <90 mm Hg. The main criteria for exclusion were body mass index >40 kg/m 2 , ventricular rhythm disorders, hematuria or leukocyturia, plasma creatinine >150 μmol/l, kalemia <3.5 or >5.5 mmol/l, uric acid >536 μmol/l, and treatment with potassium supplements or insulin. After a 4-week placebo run-in period, patients were randomized to 1 year of double-blind treatment with indapamide SR 1.5 mg or enalapril 10 mg. After 6 weeks of monotherapy and every 6 weeks thereafter, a stepped open-label forced titration scheme was put into effect if SBP was ≥140 mm Hg and/or DBP was >85 mm Hg. For the first step, amlodipine 5 mg once daily was added and could be followed 6 weeks later by an uptitration to amlodipine 10 mg. Atenolol 50 mg could be added thereafter as a second add-on treatment and uptitrated to 100 mg 6 weeks later. The NESTOR study followed Good Clinical Practice and was approved by the appropriate Ethics Committees. Each patient gave written informed consent.
Patients were included in this retrospective post-hoc subanalysis if they were uncontrolled on monotherapy and were given add-on amlodipine 5 mg as the first step: 135 patients in the indapamide SR/amlodipine group and 156 patients in the enalapril/amlodipine group. A subanalysis was also performed in the subset of patients who were uptitrated to amlodipine 10 mg (62 patients in the indapamide SR group and 77 patients in the enalapril group).
Analyses of supine BP, safety data, and duration of treatment were carried out at the end of the exposure to the combination with amlodipine. Laboratory data were analyzed at the end of the 52-week study. Samples were processed at a central laboratory. Creatinine clearance was calculated using the Cockcroft formula.
For BP data, between-group comparisons for changes from baseline were performed using a linear model for analysis of covariance with treatment as a factor and baseline as a covariate. To compare effects on SBP and DBP, the ratio of the changes from baseline in SBP and DBP were calculated (ΔSBP/ΔDBP) in each group. BP control was defined as supine SBP <140 mm Hg and supine DBP <90 mm Hg. Response to treatment was defined as BP control, a reduction from baseline in supine SBP ≥20 mm Hg, or a reduction from baseline in supine DBP ≥10 mm Hg. Severity of hypertension was defined according to the highest BP value, whether SBP or DBP: for grade 1, SBP = 140-159 mm Hg and/or DBP = 90-99 mm Hg; for grade 2, SBP = 160-179 mm Hg and/or DBP = 100-109 mm Hg; and for grade 3, SBP ≥180 mm Hg and/or DBP ≥110 mm Hg. Changes from baseline in laboratory data are presented as estimates ± SE. All statistical analyses were performed in the intent-to-treat population (patients that received at least one dose of amlodipine) using SAS/PC Software version 9.2 (SAS Institute, Cary, NC).
RESULTS
Demographic data were generally similar between groups (Table 1) , though slight variations were noted. In the indapamide SR/amlodipine group, more patients were over the age of 65 (39% vs. 35%; P = not significant (NS)), median duration of hypertension was longer (106 vs. 71 months; P < 0.05), and more patients had been previously treated with RAAS inhibitors or CCBs (P = NS).
Median duration of treatment was 52.1 weeks in both groups. At the end of the 6 weeks of monotherapy, SBP/ DBP was similar between groups with 154 ± 13/91 ± 8 mm Hg in the indapamide SR/amlodipine group and 155 ± 12/90 ± 8 mm Hg in the enalapril/amlodipine group (P = NS for SBP and DBP).
At the end of treatment, supine SBP/DBP had decreased from baseline by 26 ± 13/14 ± 9 mm Hg in the indapamide SR/ amlodipine group and by 21 ± 14/11 ± 9 mm Hg in the enalapril/amlodipine group ( Figure 1A) . The difference between groups was statistically significant for SBP (−4 ± 1 mm Hg; P = 0.006), and showed a trend for DBP (−2 ± 1 mm Hg; P = 0.08). At the end of treatment, BP control was observed in 51.5% of patients in the indapamide SR/amlodipine group and in 45.7% of patients in the enalapril/amlodipine group ( Figure 1B ) (P = NS). A BP response was observed in 85.4% of patients in the indapamide SR/amlodipine group and 78.2% of patients in the enalapril/amlodipine group (P = NS).
Among patients with grade 2 or grade 3 hypertension, the superiority of the indapamide SR/amlodipine combination was preserved ( Figure 1C ). The SBP/DBP decrease from baseline was 28 ± 12/14 ± 9 mm Hg in the indapamide SR/amlodipine group and 23 ± 15/11 ± 9 mm Hg in the enalapril/amlodipine group (P < 0.05).
Subgroup of patients treated with amlodipine 10 mg
Median treatment duration was 52.1 weeks in both groups. At the end of the 6 weeks of monotherapy, SBP/ DBP was similar between groups with 158 ± 14/93 ± 6 mm Hg in the indapamide SR/amlodipine 10 mg group and 156 ± 12/92 ± 8 mm Hg in the enalapril/amlodipine 10 mg group. At the end of the amlodipine 5 mg treatment period just prior to uptitration to amlodipine 10 mg, SBP/DBP was similar between groups with additional reductions compared to the end of monotherapy of 7 ± 2/3 ± 1 mm Hg in the indapamide SR/amlodipine group and 6 ± 2/3 ± 1 mm Hg in the enalapril/amlodipine group. Age in years, mean ± SD 60.9 ± 9.9 59.9 ± 9.8 60. Abbreviations: BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; ITT, intent-to-treat; Q, quartile; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure; SR, slow release. a Significant differences between groups (P = 0.03). Grade of hypertension was defined according to the highest level of blood pressure value, whether SBP or DBP: for grade 1 SBP = 140-159 mm Hg and/or DBP = 90-99 mm Hg; for grade 2 SBP = 160-179 mm Hg and/or DBP = 100-109 mm Hg; and for grade 3 SBP ≥180 mm Hg and/or DBP ≥110 mm Hg. Isolated systolic hypertension (ISH) was graded according to SBP. 5 At the end of treatment, SBP/DBP had decreased from baseline by 26 ± 13/13 ± 9 mm Hg in the indapamide SR/ amlodipine 10 mg group and by 20 ± 13/12 ± 8 mm Hg in the enalapril/amlodipine 10 mg group. The difference between groups was statistically significant for SBP (−5 ± 2 mm Hg; P = 0.02; Figure 2A ), but not for DBP (−1 ± 1 mm Hg; P = 0.6). Moreover, the uptitration from 5 to 10 mg amlodipine was accompanied by a stronger incremental reduction in SBP in the indapamide SR/amlodipine 10 mg group (−12 ± 2 mm Hg) than in the enalapril/amlodipine 10 mg group (−8 ± 2 mm Hg). At the end of the study, this SBP-specific efficacy translated into a ΔSBP/ΔDBP ratio of 2.1 in the indapamide SR/amlodipine 10 mg group and of 1.8 in the enalapril/amlodipine group.
BP control was observed in 50.0% of patients in the indapamide SR/amlodipine 10 mg group and 45.8% of patients in the enalapril/amlodipine 10 mg group ( Figure 2B ) (P = NS). A BP response was observed in 86.2% of patients in the indapamide SR/amlodipine 10 mg group and 77.8% of patients in the enalapril/amlodipine 10 mg group (P = NS).
Among patients with grade 2 or grade 3 hypertension, treatment resulted in an SBP/DBP reduction from baseline of 28 ± 14/14 ± 10 mm Hg in the indapamide SR/amlodipine 10 mg group and a reduction of 22 ± 13/12 ± 8 mm Hg in the enalapril/amlodipine 10 mg group (P = 0.06 for ΔSBP and P = 0.4 for ΔDBP; Figure 2C ).
Laboratory parameters
In both treatment groups, creatinine clearance and natremia decreased slightly while fasting glucose increased, with no differences between groups ( Table 2) . As expected with diuretics, slight changes in uric acid (28 vs. 2 μmol/l, P = 0.003) and kalemia (−0.29 vs. 0.07 mmol/l, P < 0.0001) were observed in the indapamide SR/amlodipine group. A slight increase in alkaline phosphatase was observed with enalapril/amlodipine but not with indapamide SR/amlodipine (P < 0.01). No significant differences in aspartate aminotransferase, alanine aminotransferase, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were noted between the 2 treatment groups.
Regarding microalbuminuria, urine albumin:creatinine ratio decreased by 40.3% in the indapamide SR/amlodipine group and 44.4% in the enalapril/amlodipine group. Differences between groups were not statistically significant.
Safety
Treatment was well tolerated in both groups. Nine patients in the indapamide SR/amlodipine group and 10 patients in the enalapril/amlodipine group withdrew from the study. Among these patients, 4 patients were in the indapamide SR/amlodipine 10 mg group and 3 were in the enalapril/amlodipine 10 mg group. Adverse events were the cause of these withdrawals for 5 patients in the indapamide SR/amlodipine group (2 Table 2 . Changes in metabolic parameters (ITT population) Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BL, baseline; HDL, high-density lipoprotein; ITT, intentto-treat; LDL, low-density lipoprotein; SR, slow release.
a Mean ± SD. b Estimate ± SE. c Significant changes within group. d Significant differences between groups, P < 0.01. e Significant differences between groups, P < 0.001.
patients from the 10 mg group) and for 4 patients in the enalapril/amlodipine group (1 patient from the 10 mg group). Coughing, hypokalemia, and headache were the most frequently reported treatment-related adverse events with indapamide SR/amlodipine, while coughing, aggravated hypertension, dizziness, and bradycardia were reported most frequently in the enalapril/amlodipine group (Table 3) . When edema was specifically investigated, lower rates were reported in the indapamide SR/amlodipine group than in enalapril/amlodipine group both in the whole cohort and in 10 mg subgroup. Weight remained stable over the 52 weeks with mean changes of −0.3 kg in all groups except for +0.1 kg in the enalapril/amlodipine 10 mg group. No cases of somnolence, palpitations, abdominal pain, or nausea were reported with indapamide SR/amlodipine at any dosage.
DISCUSSION
In this retrospective analysis, the effects of combination treatment with indapamide SR/amlodipine were compared to that of enalapril/amlodipine in hypertensive patients with type 2 diabetes mellitus and microalbuminuria. Results showed that decreases in SBP were significantly greater in the indapamide SR/amlodipine group than in the enalapril/ amlodipine group regardless of severity and that laboratory parameters and adverse event rates were generally similar between the 2 groups. In particular, few patients experienced edema and changes in fasting glucose, lipids, natremia, and creatinine clearance were similar between the 2 groups.
The significantly greater decrease in SBP in the indapamide SR/amlodipine group compared to the enalapril/amlodipine group (26 vs. 21 mm Hg) is of particular note because SBP has been shown to be more difficult to control than DBP 23 and to correlate strongly with reduced cardiovascular risk and events. [24] [25] [26] This decrease in SBP is also consistent with the data from the NATIVE and EFFICIENT studies, in which SBP decreased by 33 and 29 mm Hg, respectively, after treatment with indapamide SR/amlodipine. 17, 27 The antihypertensive efficacy ratio, which was greater in the indapamide SR/amlodipine group than in the enalapril/ amlodipine group (2.1 vs. 1.8), highlights the relative effect of a treatment on SBP compared to DBP. These data underscore the strong effect of indapamide SR/amlodipine treatment on SBP. This specific effect for SBP is also supported by the EFFICIENT study, in which the SBP/DBP ratio was between 2.5 and 2.9 in the most severe patients. 17, 28 In addition, whereas add-on of 5 mg amlodipine resulted in similar decreases in SBP in both groups (−7 mm Hg in the indapamide SR/amlodipine 10 mg group and −6 mm Hg in the enalapril/amlodipine 10 mg group compared to end of monotherapy), uptitration from 5 to 10 mg amlodipine resulted in a similar incremental decrease in the enalapril/ amlodipine 10 mg group (−8 mm Hg), but a significantly greater decrease (−12 mm Hg) in the indapamide SR/ amlodipine 10 mg group. These data suggest a more fully additive BP lowering effect of amlodipine in the combination with indapamide SR.
In other clinical trials, indapamide and amlodipine have already been shown to confer long-term cardiovascular, cerebrovascular, and mortality benefits. [12] [13] [14] [15] The effective BP decrease observed in this study with the indapamide SR/ amlodipine combination suggests the potential for longterm cardiovascular benefits. 26 Treatment with indapamide SR/amlodipine was well tolerated with similar rates of adverse events in the 2 groups. The most frequently reported adverse events in each group were consistent with the known safety profiles of indapamide SR, amlodipine, and enalapril. The indapamide SR/amlodipine combination lead to higher rates of hypokalemia than enalapril/amlodipine, but rates were altogether low. Interestingly, fewer cases of edema, an adverse event expected to occur with amlodipine, were reported in the indapamide SR/amlodipine group than in the enalapril/amlodipine group, which as an angiotensin-converting enzyme inhibitor-based strategy is already known to reduce CCB-associated edema by approximately 50%. These indapamide SR/amlodipine data are Table 3 . Treatment-related adverse events reported by more than 1 patient and noteworthy adverse events (ITT population) consistent with those published in the EFFICIENT study, in which no cases of peripheral edema were reported after indapamide SR/amlodipine treatment. 28 The authors of EFFICIENT suggest that the reduced risk of amlodipine-associated edema may be linked to indapamide-induced postcapillary venous relaxation which counterbalances the amlodipine-associated increase in vasodilatation in the precapillary vessels. 27, 29 Lastly, although guidelines cite nephroprotective properties as the rational for always including a RAAS inhibitor in combination therapies for diabetic patients, this study, shows that effects on renal parameters were the same in the indapamide SR/amlodipine and enalapril/amlodipine groups. Thiazide-like diuretics are often included in the same class of antihypertensives as thiazide-type diuretics. Differences in mechanisms of action, pleiotropic effects, metabolic and renal effects, and short and long-term efficacy, 20, 30, 31 however, are such that it is paramount that the data in this paper not be extrapolated to a hydrochlorothiazide/amlodipine combination. In particular, hydrochlorothiazide has been shown to increase all-cause mortality by 16% compared to placebo in the MRFIT trial, whereas treatment with an indapamide-based regimen in the HYVET trial resulted in a 21% decrease in all-cause mortality compared to placebo. 15, 32 Consistent with this line of thought, the European Society of Hypertension (ESH) guidelines indicate that "it has been also argued that diuretics such as chlorthalidone or indapamide should be used in preference to conventional thiazide diuretics such as hydrochlorothiazide. " 5
Study limitations
Although the NESTOR trial was randomized for study treatments (indapamide SR and enalapril), the present posthoc, retrospective analysis was not randomized and accordingly there are slight differences in baseline characteristics between the 2 treatment groups. More patients in the indapamide SR/amlodipine group were over 65 years of age, had grade 2 or 3 hypertension, had been previously treated with RAAS inhibitors and CCBs, and had been hypertensive for longer. Results reported herein are therefore only valid for this patient population and at the dosages used in the study. Nonetheless, it is important to note that these baseline data suggest that these indapamide SR/amlodipine patients would be harder to treat than the patients in the enalapril/amlodipine group. In addition, the impact of study treatment on fasting glucose and potassium could not be assessed rigorously as physicians were allowed to adjust antidiabetic treatments and potassium supplements as needed. Lastly, due to safety data management, emergence of adverse events was defined from baseline and included adverse events occurring during the 6 weeks of monotherapy.
Conclusions
Fifty-two weeks of treatment with indapamide SR/ amlodipine safely lowered BP. This thiazide-like diuretic/ CCB combination may offer a safe and effective alternative to combination treatments containing RAAS inhibitors in hypertensive patients with diabetes and microalbuminuria.
